Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model
Open Access
- 29 April 2018
- journal article
- Published by Impact Journals, LLC in Oncoscience
- Vol. 5 (3-4) , 99-108
Abstract
Claudin-low triple negative breast cancer (CL-TNBC) is a clinically aggressive molecular TNBC subtype characterized by a propensity to metastasize, recur and acquire chemoresistance. CL-TNBC has a diverse intra- and extracellular composition and microenvironment, and currently there are no clinically approved targeted therapies. Histone deacetylase inhibitors (HDACi) have been investigated as therapeutic agents targeting invasive TNBC phenotypes. However, further studies are required to evaluate HDAC inhibition in CL-TNBC. Here, we utilize a novel CL- TNBC patient-derived xenograft model to study the various and diverse therapeutic potential targets within CL-TNBC tumors. To evaluate effects of the pan-HDACi panobinostat on metastasis and the mesenchymal phenotype of CL-TNBC, we utilize immunohistochemistry staining and qRT-PCR in in vitro, ex vivo and in vivo studies. Further, we evaluate pan-HDAC inhibition on stem-like subpopulations using 3D mammosphere culture techniques and quantification. Finally, we show that pan- HDACi suppresses collagen expression in CL-TNBC. In this study, we provide evidence that pan-HDAC inhibition has effects on various components of the CL-TNBC subtype, and we demonstrate the potential of our novel CL-TNBC PDX model in therapeutic discovery research.Keywords
This publication has 33 references indexed in Scilit:
- Patient-derived breast tumor xenografts facilitating personalized cancer therapyBreast Cancer Research, 2013
- Dissecting the Heterogeneity of Triple-Negative Breast CancerJournal of Clinical Oncology, 2012
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancerBritish Journal of Cancer, 2011
- Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerBreast Cancer Research, 2010
- Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patientsBreast Cancer Research, 2009
- Collagen density promotes mammary tumor initiation and progressionBMC Medicine, 2008
- Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapyBreast Cancer Research, 2008
- Regulation of Tissue-Specific and Extracellular Matrix-Related Genes by a Class I Histone DeacetylaseMolecular Cell, 2005
- Increased expression of histone deacetylase 2 is found in human gastric cancerAPMIS, 2005